Previous 10 | Next 10 |
- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash burn guidance reduced - - Company to host conference call and webcast today at 8:00 A...
- Recommended Phase 2 dose determined for future JTX-4014 trials - - Introducing the dosing and sequencing strategy for vopratelimab and ipilimumab in ongoing EMERGE Phase 2 trial - CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a cli...
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2019 financial results...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a bumpy week last week but, in the end, still had an increase from 3,122.33 points on Monday’s (October 7) open to reach 3,152.35 points as of 1:19 p.m. EDT on Friday (October 11). In terms of top performing stocks, a number of sm...
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that safety and efficacy data for JTX-4014 and a clinica...
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with this Read more ...
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at three upcoming in...
Jounce Therapeutics, Inc. (JNCE) Q2 2019 Earnings Conference Call August 07, 2019, 08:00 ET Company Participants Komal Joshi - Head, IR & Strategic Finance Richard Murray - President, CEO & Director Elizabeth Tréhu - Chief Medical Officer Kimberlee Drapkin - CFO &a...
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Jounce Therapeutics ( JNCE ) Q2 results : Revenues: $17.4M (-10.3%). More news on: Jounce Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...